Ingalfarma joins the pool of companies associated with Fundación’s Science and Business Park


Ingalfarma is a biomedical company that develops innovative treatments aimed at solving complex oral pathologies. Its mission is to reinstate the value of oral health in the biopharmaceutical industry.

Dentoxol is Ingalfarma’s flagship product; an advanced mouthwash designed for the prevention and control of oral mucositis, a disabling and painful pathology that generates ulcerative lesions in the oral mucosa of cancer patients, during and after chemo and radiation therapies. The Chilean Health Regulatory Authority has cleared Dentoxol in Chile and it is available for purchase in specialty pharmacies.

Ingalfarma is working alongside Fundación Ciencia & Vida in its development program. The company is seeking to obtain clearance from the FDA to commercialize Dentoxol in the US and is conducting a clinical trial in Chile to accomplish that objective.


Ingalfarma’s founder team and shareholders at the closing of the investment round.